Phase 1 GC012F Dual CAR T-cell Therapy Targeting CD19 and BCMA for Multiple Myeloma

This phase 1 study is investigating GC012F in early-line treatment for multiple myeloma, including newly diagnosed high-risk and relapsed/refractory cases. The trial uses a single infusion of a dual CAR T-cell product that targets CD19 and BCMA to assess safety, feasibility, and early efficacy. AstraZeneca sponsors this multicenter study exploring a novel immunotherapy approach for this patient population.